CEL-SCI Co. (NYSEAMERICAN:CVM) shares dropped 5.9% on Monday . The stock traded as low as $6.63 and last traded at $7.61. Approximately 1,648,100 shares traded hands during mid-day trading, an increase of 177% from the average daily volume of 594,168 shares. The stock had previously closed at $8.09.
CEL-SCI (NYSEAMERICAN:CVM) last issued its quarterly earnings data on Thursday, February 14th. The company reported ($0.17) earnings per share for the quarter. The company had revenue of $0.13 million during the quarter.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. purchased a new position in shares of CEL-SCI during the first quarter worth $56,000. Renaissance Technologies LLC purchased a new position in shares of CEL-SCI during the first quarter worth $629,000. Commonwealth Equity Services LLC boosted its position in shares of CEL-SCI by 426.7% during the first quarter. Commonwealth Equity Services LLC now owns 102,455 shares of the company’s stock worth $362,000 after buying an additional 83,004 shares during the period. Advisor Group Inc. boosted its position in shares of CEL-SCI by 6.4% during the first quarter. Advisor Group Inc. now owns 33,378 shares of the company’s stock worth $118,000 after buying an additional 2,000 shares during the period. Finally, Thoroughbred Financial Services LLC boosted its position in shares of CEL-SCI by 21.1% during the first quarter. Thoroughbred Financial Services LLC now owns 13,921 shares of the company’s stock worth $49,000 after buying an additional 2,428 shares during the period.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.
Featured Article: How Short Selling Works
Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.